ST. LOUIS, Jan. 6, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq: STXS ), a leading provider of innovative technologies for the treatment of cardiac arrhythmias, announced today that more than 75,000 patient cases have been completed with its remote magnetic navigation technology. The Company also announced that it will present the latest enhancements and clinical data for its industry leading robotic platform at the upcoming International AF Symposium, January 8-10, 2015 in Orlando, FL (Booth #816). Now in its 20 th year, the annual three-day symposium brings together the world's leading medical scientists and providers to discuss the most recent advances in the field of atrial fibrillation.
First commercialized in 2003, Stereotaxis remote magnetic navigation technology is designed for the safe, effective and efficient facilitation of complex cardiac ablation. The Company's fourth generation remote navigation system, the Niobe® ES system, was launched in December 2011 and, together with its Vdrive® robotic navigation system and Odyssey™ solutions portfolio, comprises the Epoch™ Solution, a fully remote electrophysiology (EP) platform. Today, the Niobe system is installed in 177 EP sites worldwide and supported by over 200 peer-reviewed publications.
"The expanding experiential and clinical body of evidence continues to confirm the outstanding performance of our Epoch platform in safety, procedure efficiency and outcomes," said William C. Mills, Stereotaxis Chief Executive Officer. "We are excited to advance the dialogue with the International AF Symposium participants concerning the immediate and long-term efficacy of our system in treating complex arrhythmias through ablation therapy."
During a Product Theatre lunch session on January 8, Stereotaxis physician users will discuss how Stereotaxis' latest advancements are improving the success of their ablation programs. Moderated by Dr. Andrea Natale, Executive Director for the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, TX, the afternoon's presenters include Dr. David Burkhardt (Texas Cardiac Arrhythmia Institute), Dr. William Spear (Advocate Christ Medical Center, Oak Lawn, IL) and Dr. Erik Wissner (Asklepios Klinik St. Georg, Hamburg, Germany).
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch ™ Solution includes the Niobe ® ES remote magnetic navigation system, the Odyssey ® portfolio of lab optimization, networking and patient information management systems and the Vdrive ™ robotic navigation system and consumables.
The core components of Stereotaxis systems have received regulatory clearance in the U.S., European Union, Canada, China, Japan and elsewhere. The V-Sono ™ ICE catheter manipulator, V-Loop ™ variable loop catheter manipulator and V-CAS ™ catheter advancement system have received U.S. clearance. For more information, please visit www.stereotaxis.com .
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Investor Contact: Martin Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300
